Feasibility and Safety of a Novel Bland Embolization using Ekobi Embolization Microspheres in an Office Based Lab

Dr. Edgar St. Amour; CARTI Cancer Center, Little Rock, AR

Purpose

To evaluate the feasibility and safety of using biodegradable Ekobi embolization microspheres in an office based interventional oncology practice.

Materials and Methods

Retrospective chart review of bland embolization utilizing Ekobi microspheres between January and June 2020 in 3 patients who were previously treated with Yttrium 90 and were poor candidates for further radioembolization. Feasibility was defined as a patient tolerating the treatment in an office based lab without requiring hospitalization. Safety was defined as no major adverse events at the time of, and subsequent to, the treatment.

Results

All patients were able to undergo bland embolization utilizing Ekobi microspheres in an office based lab without need for hospitalization. Only one patient had post-procedure symptoms, and that was fatigue which lasted approximately 1 week. No patient had any significant post-embolization pain and none developed post-embolization syndrome. No patient had any significant change in their liver function tests, and those with imaging all had stable disease up to 3 months. Two patients had a total of 400 mg of Ekobi microspheres injected, while the third had 800 mg injected.

Conclusion

Bland embolization using Ekobi embolization microspheres is both safe and feasible when used in an office based lab. There were no major adverse events or need for hospitalization. Ekobi microspheres may be an excellent alternative to other embolization products, and further research is warranted to evaluate response to treatment with comparison to established embolization techniques.

CIO Meeting - October 22-24, 2020;